Intact Investment Management Inc. Grows Stock Holdings in Humana Inc. (NYSE:HUM)

Intact Investment Management Inc. boosted its stake in Humana Inc. (NYSE:HUM - Free Report) by 633.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,800 shares of the insurance provider's stock after purchasing an additional 7,600 shares during the period. Intact Investment Management Inc.'s holdings in Humana were worth $4,029,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Russell Investments Group Ltd. increased its holdings in Humana by 59.0% in the fourth quarter. Russell Investments Group Ltd. now owns 338,801 shares of the insurance provider's stock valued at $154,948,000 after purchasing an additional 125,697 shares during the period. Darrow Company Inc. acquired a new stake in Humana in the fourth quarter valued at $207,000. Meritage Portfolio Management increased its holdings in Humana by 83.9% in the fourth quarter. Meritage Portfolio Management now owns 32,389 shares of the insurance provider's stock valued at $14,828,000 after purchasing an additional 14,778 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its holdings in Humana by 4.2% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,731 shares of the insurance provider's stock worth $1,250,000 after acquiring an additional 111 shares during the period. Finally, Atria Wealth Solutions Inc. grew its holdings in Humana by 10.8% during the 4th quarter. Atria Wealth Solutions Inc. now owns 3,157 shares of the insurance provider's stock worth $1,446,000 after acquiring an additional 307 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Jorge S. Mesquita purchased 545 shares of Humana stock in a transaction dated Tuesday, February 20th. The stock was purchased at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the transaction, the director now directly owns 2,578 shares of the company's stock, valued at $946,358.02. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.32% of the company's stock.

Humana Stock Performance

Humana stock traded down $5.51 during mid-day trading on Friday, reaching $305.90. The company's stock had a trading volume of 1,213,131 shares, compared to its average volume of 1,914,716. Humana Inc. has a 12-month low of $299.23 and a 12-month high of $541.21. The company has a market capitalization of $36.86 billion, a P/E ratio of 19.05, a PEG ratio of 1.79 and a beta of 0.45. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.59 and a current ratio of 1.67. The firm's fifty day moving average price is $327.77 and its two-hundred day moving average price is $393.91.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating analysts' consensus estimates of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The business had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same period in the previous year, the business earned $9.38 EPS. Humana's revenue was up 10.7% compared to the same quarter last year. Sell-side analysts predict that Humana Inc. will post 16.08 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.16%. Humana's dividend payout ratio (DPR) is currently 22.04%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Jefferies Financial Group decreased their price target on Humana from $411.00 to $381.00 and set a "buy" rating for the company in a report on Monday, April 22nd. Stephens decreased their price target on Humana from $550.00 to $430.00 and set an "overweight" rating for the company in a report on Friday, January 26th. Barclays decreased their price target on Humana from $356.00 to $310.00 and set an "equal weight" rating for the company in a report on Tuesday, April 2nd. Bank of America reiterated a "neutral" rating and set a $342.00 price target (down from $470.00) on shares of Humana in a report on Tuesday, April 2nd. Finally, StockNews.com downgraded Humana from a "strong-buy" rating to a "hold" rating in a report on Friday, January 26th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $424.50.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.